| This week's sponsor is ReSolution Latin America. | | | |
Today's Rundown Realm tanks again as second drug fails phase 2 Batycky exits Acorda to head up new biotech Bioverativ executive Rogerio Vivaldi to helm cell therapy producer Sigilon [Sponsored] Rooted in Purpose: One Company’s Journey toward the First Treatment for a Rare Lung Disease Insilico, Juvenescence and the Buck Institute form AI-based venture to tackle metabolism and aging-related diseases Bayer, Haplogen ink R&D deal for pulmonary diseases Allergan taps Pfizer oncology veteran as CMO for some crucial pipeline help Featured Story | | | Tuesday, August 14, 2018 Realm Therapeutics has reported its second midphase flop of the year. The setback threatens to wipe out Realm’s clinical-phase pipeline, leaving the immunology player with just a preclinical acne asset that features the same active ingredient as the failed programs. |
|
|
| This week's sponsor is Catalent. | | | Article | The Importance of Clinical Returns Planning
Study sponsors often focus on upfront planning to ensure clinical sites are prepared to reach study milestones but ignore the logical challenges of managing their clinical returns. Learn how developing a forward-thinking plan to manage clinical returns can reduce study close out risk. |
Top Stories Tuesday, August 14, 2018 Acorda Therapeutics’ chief technology officer, Rick Batycky, Ph.D., is leaving the company next week after four years in the role to head up his own operation. Tuesday, August 14, 2018 Sigilon Therapeutics is bringing on Bioverativ’s chief global therapeutic operations officer, Rogerio Vivaldi, M.D., to serve as its CEO. The change comes as Sigilon plans to move its cell-based therapeutic implants into the clinic for phase 1 trials. Monday, August 13, 2018 With a novel therapy under FDA review, Insmed hopes to change the treatment paradigm for patients in the U.S. suffering from a rare and debilitating lung disease. Tuesday, August 14, 2018 A triumvirate of aging-focused biotechs and researchers—the AI company Insilico Medicine, the portfolio-based startup Juvenescence and the nonprofit Buck Institute—have formed a new joint venture to develop small molecules for a novel target in a bid to extend life spans. Tuesday, August 14, 2018 Bayer and Evotec partner Haplogen will work to identify new treatments for pulmonary conditions including chronic obstructive pulmonary disease under a multiyear drug discovery and development collaboration. Tuesday, August 14, 2018 As Allergan enters a key phase for its late-stage products, it’s bringing in a veteran executive for backup. The Dublin drugmaker has poached Charles Hugh-Jones, the chief medical officer at Pfizer Oncology, to serve as its new SVP and chief medical officer. | This week's sponsor is FierceBiotech. | | | |
Resources Sponsored by: Patheon, part of Thermo Fisher Scientific “Faster and better” has become the mantra for biopharmaceutical companies as they face intense pressure to get therapies to market faster. Quickly proving efficacy in first-in-human (FIH) trials is a make-or-break milestone for these cash-strapped companies whose hopes hinge upon one or two molecules. Read how CDMOs are responding to this pressure. Sponsored by: PharmaCord When was the last time your patient support program perfectly aligned with the patient journey, solving all the critical gaps in positioning your brand for success? Follow the 3-D approach to your solution design, and you will achieve a better outcome for your patients. Sponsored by: WCG Selecting the right sites is the most crucial decision you’ll make in your next clinical trial, and the single most important factor to consider in selecting a site is whether or not it can meet its enrollment goals. Sponsored by: Veeva Industry Research: See new results from one of the industry's largest, global clinical operations surveys. Sponsored by: Medidata Accelerate Clinical Research as Study Complexity Grows Sponsored by: Veeva Ready to modernize your RIM environment? Secure buy-in with these tips. Sponsored by: Catalent Develop a basic understanding of principles and concepts of bioavailability of oral drugs. Drug Approval, Manufacturing Quality & Regulation 2018 | Online BIO Latin America 2018 September 4-5, 2018 | São Paulo, Brazil RESI HealthTech Week September 5-7, 2018 | Boston, MA 4th Annual Bio/Pharmaceutical Product Launch Summit September 25-26, 2018 | Cambridge, MA Drug Development Immersion September 26-27, 2018 | West Windsor, NJ FierceBiotech 3rd Drug Development Forum October 1–3, 2018 | Hilton Boston Logan Airport Hotel | Boston, MA Compliance Certification Program at Seton Hall Law October 8-11, 2018 | Newark, NJ BioImmersion: Biotech for the Non-Scientist October 16-18, 2018 | Chicago, IL 2018 BIO Investor Forum October 17-18, 2018 | Westin St. Francis, San Francisco, CA FierceBiotech Executive Summit: London October 30, 2018 | Royal Society of Medicine Drug Development Boot Camp® 2018 – Register Now! November 14-15, 2018 | Boston, MA | Register now and start your pre-Boot Camp preparation Field Service Amsterdam November 27-28, 2018 | NH Collection Amsterdam Grand Hotel Krasnapolsky | 